News

News and Press Releases
Clinical Trials | Researcher Resources | Cystic Fibrosis Foundation Therapeutics (CFFT) Drug Company Ends Ataluren Program for CF Nonsense Mutations

PTC Therapeutics has discontinued development of ataluren as a potential treatment for people with cystic fibrosis caused by a nonsense mutation. The Cystic Fibrosis Foundation is supporting efforts to pursue treatments for people with CF who have a nonsense, splicing or other rare mutations. 

| 3 min read
About the CF Foundation | Cystic Fibrosis Foundation Therapeutics (CFFT) CF Foundation Opens One-of-a-Kind Research Lab

Expanded Research Lab to Apply Latest Scientific Advances -- Including Stem Cell Research and Gene Editing -- to Accelerate New Treatments for CF

| 3 min read
About the CF Foundation | Cystic Fibrosis Foundation Therapeutics (CFFT) | Research Cystic Fibrosis Foundation Therapeutics Announces $14 Million Research Expansion with Genzyme

Program Aimed at Advancing Search for Therapies Targeting Most Common Mutation of CF

| 3 min read